U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07788105) titled 'Efficacy and Safety of Lanoracopan in the Treatment of PNH' on Aug. 23.
Brief Summary: This study aimed to evaluate the efficacy and safety of Lanoracopan Hydrochloride in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study Start Date: Sept., 2026
Study Type: OBSERVATIONAL
Condition:
Paroxysmal Nocturnal Hemoglobinuria, PNH
Intervention:
DRUG: Lanoracopan Hydrochloride
400mg bid
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Peking Union Medical College Hospital
Information provided by (Responsible Party): Bing Han, Peking Union Medical College Hospital
Disclaimer: Curated by HT Syndication....